Treatment patterns, outcomes, healthcare resource utilization, and costs associated with locally advanced squamous cell carcinoma of the head and neck in Japan
This real-world study demonstrates that treatment of patients with LA SCCHN in Japan often included definitive nonsurgical treatment or primary surgery. The substantial burden related to LA SCCHN-associated HCRU and considerable percentage of patients receiving no treatment highlights a need for novel and effective therapies for LA SCCHN.
Authors
- Makoto Tahara (ORCID: https://orcid.org/0000-0001-9035-3106)
- Ramzi Argoubi (ORCID: https://orcid.org/0000-0002-3171-0078)
- Sarah Bobiak (ORCID: https://orcid.org/0000-0001-9452-0063)
- Makan Rahshenas
- Ken‐ichi Nibu (ORCID: https://orcid.org/0000-0002-5461-4871)
- Noriko Yoshimi (ORCID: https://orcid.org/0000-0002-0124-0634)
- Ember Lu
- Vanessa Rascon-Velasco
Institutions
- Merck KGaA, Darmstadt (Germany) (DE)
- Kobe University Hospital (JP)
- Merck Serono S.A. (Switzerland) (CH)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- National Cancer Center Hospital East (JP)
- Diagnostics for the Real World (United States) (US)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.3389/fonc.2025.1607280
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00